Advertisement
Australia markets open in 29 minutes
  • ALL ORDS

    8,443.70
    -35.30 (-0.42%)
     
  • AUD/USD

    0.6746
    -0.0016 (-0.24%)
     
  • ASX 200

    8,176.90
    -28.50 (-0.35%)
     
  • OIL

    74.06
    +0.49 (+0.67%)
     
  • GOLD

    2,639.90
    +4.50 (+0.17%)
     
  • Bitcoin AUD

    92,205.79
    -1,529.40 (-1.63%)
     
  • XRP AUD

    0.79
    -0.01 (-1.39%)
     

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sutro Biopharma, Inc.
Sutro Biopharma, Inc.

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host a Research Forum to highlight its pipeline of next-generation ADCs. The live webcast will be held on Thursday, October 10, 2024, starting at 1:30 p.m. PT / 4:30 p.m. ET.

Webcast Information:
To access the live audio webcast on Thursday, October 10, at 1:30 p.m. PT / 4:30 p.m. ET, please go to https://ir.sutrobio.com/news-events/ir-calendar

An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Sutro Biopharma
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

CONTACT: Contact Emily White Sutro Biopharma (650) 823-7681 ewhite@sutrobio.com